At the forefront of pharmaceutical innovation, Virupaksha stands as a beacon of excellence in manufacturing high-purity Fluconazole, crucial for treating severe infections like cryptococcal meningitis. With an unwavering commitment to quality and safety, the company operates under stringent WHO-GMP guidelines, ensuring that every batch produced meets international standards for efficacy and purity.
Their state-of-the-art facilities are not only ISO 9001 certified—confirming their dedication to consistent quality management—but also ISO 14001 certified, highlighting their proactive approach to environmental sustainability in production processes. This meticulous attention to detail underscores Virupaksha’s mission: delivering pharmaceuticals that healthcare professionals can trust while contributing positively to the global community’s health outcomes.
Other Latest News
- 7th Supply Chain & Logistics for Cell & Gene Therapies Summit to Take Place in Arlington, VA March 10, 2026 4:58 am SupplyChainBrain The 7th Supply Chain & Logistics for Cell & Gene Therapies Summit is the only industry-led forum exclusively dedicated to advancing supply chain and logistics strategies for advanced therapies, at a time when the sector faces unprecedented …
- Smarter Filings, Smarter Factories March 10, 2026 12:54 am Genetic Engineering and Biotechnology News Artificial intelligence (AI) is no longer a futuristic add-on in the life sciences. It is rapidly becoming infrastructure. Across regulatory affairs and biomanufacturing, AI systems are moving from experimental pilots into validated, production-grade tools …
- Design Evolution of Curcumin-Loaded Nanostructured Lipid Carriers: Formulation Strategies, Functional Modifications, and Mechanistic–Translational Perspectives March 9, 2026 8:07 pm Dove Medical Press Introduction Curcumin, a polyphenolic compound derived from the rhizome of Curcuma longa, has gained substantial attention due to its wide-ranging pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, antidiabetic, anticancer …
- Three European stocks to buy for long-term growth and income March 9, 2026 9:33 am MoneyWeek Follow us Add us as a preferred source on Google Newsletter Get the MoneyWeek Newsletter Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your …
- Middle East tensions are hammering banks; Narendra Solanki says buy the dip March 9, 2026 9:22 am ETBFSI.com Indian equities are under sharp pressure, and banking stocks have borne the brunt of the selloff. But Narendra Solanki, Head of Fundamental Research at Anand Rathi Shares & Stock Brokers, has a clear message for long-term investors: this is a buying …
- Japan Contract Sterile Fill-Finish Services Market Growth Projections US$398.28Mn by 2033 | Growth Biologics & Vaccines March 9, 2026 6:53 am EIN Presswire Japan Contract Sterile Fill-Finish Services Market Expands as Biologics Manufacturing and Regulatory Support Accelerate Outsourcing Demand TOKYO, OSAKA, JAPAN, March 9, 2026 /EINPresswire.com/ -- Market Size and Growth 2026: The rapid rise …
- 24 stocks in focus today: Tata Power, UltraTech Cement, Go Digit, RailTel, Lupin, Cipla, GAIL & more March 9, 2026 6:29 am The Hindu Business Line The board of Samhi Hotels has approved a significant investment to acquire 70 per cent partnership interest and equivalent profit share in Rare India for ₹47.39 crore. Rare India is a New Delhi-based partnership firm specialising in conscious luxury travel …
- Most women CEOs in FMCG and pharma March 9, 2026 6:20 am ETBrandEquity.com A survey by global search firm Executive Access shows the FMCG sector has the highest number of women CEOs, with a 19% share. Pharma, too, has built a strong management bench that is increasingly feeding into top leadership roles, and follows with a 17% …
- Label Applicators Market Set for Rapid Growth as Automation Transforms Packaging Industry 2026 | DataM Intelligence March 9, 2026 5:09 am EIN Presswire The Global Label Applicators Market is estimated to reach at CAGR of 5.1% during the forecast period (2024-2031). AUSTIN, TX, UNITED STATES, March 9, 2026 /EINPresswire.com/ -- Market Overview: The Label Applicators Market plays a vital role …
- Share Market Highlights 9th March 2026: Sensex, Nifty sink nearly 2% on surging crude oil prices, West Asia turmoil March 9, 2026 1:52 am The Hindu Business Line Markets to open lower as Iran-Israel/US hardening their stance, global investors are suffering as economic fallout is going to be bigger than earlier perceived. | Photo Credit: KanawatTH Stock Market today | Share Market Highlights: BSE Sensex tanked 1 …
- Pharma ADMET Testing Market to Reach $18,062.89 Bn by 2026 as Advanced ADMET Technologies Transform Drug Development March 9, 2026 12:00 am EIN Presswire The Business Research Company's Pharma ADMET Testing Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, March 9, 2026 /EINPresswire.com/ -- "Pharma ADMET Testing Market to …
- Veterinary Drugs Market to Reach USD 60.85 Million by 2032, Driven by Preventive Animal Healthcare March 6, 2026 11:28 am EIN Presswire Veterinary Drugs Market was valued at USD 39.65 million in 2024 and is projected to reach USD 60.85 million by 2032, growing at a CAGR of 5.5% from 2025–2032. ROCKVILLE , MD, UNITED STATES, March 6, 2026 /EINPresswire.com/ -- The global …
- Biochemical Defense Market 2026: Strategic Developments Strengthening Global Security March 6, 2026 10:15 am EIN Presswire The Business Research Company's Biochemical Defense Market 2026: Strategic Developments Strengthening Global Security LONDON, GREATER LONDON, UNITED KINGDOM, March 6, 2026 /EINPresswire.com/ -- "The biochemical defense market is …
- The Clinical Pivot: How Universal NutriScience Is Rewriting Preventive Healthcare in India March 6, 2026 6:45 am ETHealthworld.com For decades, healthcare largely followed a reactive model, intervening once disease manifests. But with over 5.8 million annual deaths from non-communicable diseases (NCDs), rising metabolic disorders, infertility challenges, lifestyle-linked chronic …
- The Strategic Lever in Biomanufacturing 4.0: Discussion from the September 2025 Talent Boardroom at Biotech Week Boston March 5, 2026 9:49 pm BioProcess International Over the past decade, biopharmaceutical manufacturers have invested heavily in expanded production capacity and rapid integration of automation and digitalization. Despite those advances, a paradox has emerged in which physical and technological …
- From Bulk Chemicals to Biologics: Ireland’s Biopharmaceutical Transformation and Global Leadership March 5, 2026 9:20 pm BioProcess International Ireland’s economic-development policies in the second half of the 20th century, many designed to keep industry ownership native hands, presented little encouragement for overseas companies to invest in Ireland (1). Meanwhile, the manufacturing of most …
- Pharma majors find a faster path to new drugs with Indian GCCs March 5, 2026 2:53 pm ETGCC.in In recent years, global pharmaceutical companies have expanded their operations in India, using GCCs to handle scientific, analytical and regulatory work that was once concentrated only in the Western research hubs.Drug discovery often begins as a search …
- Pharmaceutical Quality Control Release Testing Service Market 2026-2030: Exploring Growth Trends and Recent Developments March 5, 2026 5:47 am EIN Presswire Pharmaceutical Quality Control Release Testing Service Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, March 5, 2026 /EINPresswire.com/ -- The pharmaceutical quality control release …
- GLP-1 Receptor Agonist Market 2026: Assess Market Momentum in Metabolic and Diabetes Therapies March 5, 2026 5:17 am EIN Presswire The Business Research Company's GLP-1 Receptor Agonist Market 2026: Assess Market Momentum in Metabolic and Diabetes Therapies LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2026 /EINPresswire.com/ -- "The GLP-1 Receptor Agonist …
- Europe’s pharma trade with the US remains critical despite tariff turmoil March 3, 2026 6:03 pm Pharmaceutical Technology US government policies of Most Favored Nation (MFN) and tariffs threaten to disrupt Europe’s pharmaceutical trade, but while European countries explore alternative markets in Asia, it may be difficult for them to substitute the innovation and profit …
- Introducing Seeq Intelligence: Bridging Industrial AI and Human Expertise for Smarter Operational Decisions March 3, 2026 1:36 pm Manufacturing Tomorrow Industrial organizations face growing complexity, increasing talent loss, and critical expertise that is locked in siloed systems and individual experience, making it more challenging to improve performance, create consistency, and build competitive …
- Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production March 3, 2026 12:36 pm Pharmaceutical Technology Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo’s site in Monksland, Athlone, is one of 16 facilities the company has across the world …
- BioInnovation Institute backs five startups with €1.3M in follow-on funding March 3, 2026 10:42 am Tech.eu BioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, has awarded an additional €1.3 million in follow-on funding to five portfolio startups, bringing total support per company to up to €1.8 million. The funding is intended to …
- Risk as the New Compass: Transforming Software Assurance Through Risk-Based Approach March 3, 2026 4:38 am Tech Times "Risk should be the compass, not the paperwork," said Sindhuri Korrapati, a senior software quality supervisor. It's a striking statement in a field long defined by binders, screenshots, and scripted test runs meant as much for auditors as …
- Five Danish startups enter BII’s Venture House 8 cohort with €1.3 million follow-on backing March 2, 2026 5:59 pm EU Startups BioInnovation Institute (BII), a Novo Nordisk Foundation Initiative, has provided an additional €1.3 million in follow-on funding to five portfolio startups – Synuca Therapeutics, Gefjon Pharma, MicroMiner, DARERL and Diasense – bringing the total support …